PUMA BIOTECHNOLOGY, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $12.95 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-02-26
- PUMA BIOTECHNOLOGY, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $12.95M, a 167.65% increase from fiscal 2023.
- PUMA BIOTECHNOLOGY, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $4.84M, a 29.53% decline from fiscal 2022.
- PUMA BIOTECHNOLOGY, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2022 was $6.86M, a 69.75% decline from fiscal 2021.
- PUMA BIOTECHNOLOGY, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2021 was $22.69M, a 66.10% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2024-12-31 | $12.95M 10-K · filed 2026-02-26 |
| 2023-12-31 | $4.84M 10-K · filed 2026-02-26 |
| 2022-12-31 | $6.86M 10-K · filed 2025-02-27 |
| 2021-12-31 | $22.69M 10-K · filed 2024-02-29 |
| 2020-12-31 | $13.66M 10-K · filed 2023-03-02 |
| 2019-12-31 | $21.83M 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |